Intra-articular injection of three doses of platelet lysate (PL) injected every 3-4 weeks is safe and can decrease pain and increase function in patients with knee osteoarthritis (OA).

The clinical results attained with PL are in accordance with the outcomes described for platelet-rich plasma (PRP), while mitigating few PRP-associated shortcomings. More adequately powered, multicenter, prospective, non-randomized and randomized controlled studies with extended follow-up are needed to confirm the effectiveness of PL in knee OA.

Comparative studies to help clinicians in choosing the best autologous peripheral blood-derived orthobiologic for knee OA treatment are also warranted.